Abstract
Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Current Pharmaceutical Biotechnology
Title:Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways
Volume: 18 Issue: 12
Author(s): Elisa Molinelli*, Anna Campanati, Valerio Brisigotti and Annamaria Offidani
Affiliation:
- Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona,Italy
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Abstract: Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Export Options
About this article
Cite this article as:
Molinelli Elisa*, Campanati Anna, Brisigotti Valerio and Offidani Annamaria, Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666180103140643
DOI https://dx.doi.org/10.2174/1389201019666180103140643 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Markers of Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Relationship Between Vitamin D Deficiency and Chronic Low Back Pain in Postmenopausal Women
Current Rheumatology Reviews Nitric Oxide and its Role in Ischaemic Brain Injury
Current Molecular Medicine Topical Therapy for Actinic Keratoses: Current and Evolving Therapies
Reviews on Recent Clinical Trials Recent U.S. Patents on Protein Drug Formulation: 2000-2007
Recent Patents on Drug Delivery & Formulation Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein
Mini-Reviews in Medicinal Chemistry The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs
Mini-Reviews in Medicinal Chemistry In Search of the Most Suitable Lentiviral shRNA System
Current Gene Therapy Using Cytochalasins to Improve Current Chemotherapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Beneficial Effects of Herbs, Spices and Medicinal Plants on the Metabolic Syndrome, Brain and Cognitive Function
Central Nervous System Agents in Medicinal Chemistry The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry The Oxygen Therapy
Current Medicinal Chemistry Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets In Vitro Skin Models for the Evaluation of Sunscreen-Based Skin Photoprotection: Molecular Methodologies and Opportunities
Current Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Subject Index To Volume 6
Anti-Cancer Agents in Medicinal Chemistry